Breast cancer patients clinical outcome measures are associated with Src kinase family member expression

British Journal of Cancer

Volumn 103, Issue 6, 2010, Pages 899-909

  Elsberger, B ^a   Fullerton, R ^a   Zino, S ^a   Jordan, F ^a   Mitchell, T J ^a   Brunton, V G ^b   Mallon, E A ^a   Shiels, P G ^a   Edwards, J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

breast cancer; disease specific survival; immunohistochemistry; quantitative real time PCR; Src kinase family members

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEMATOPOIETIC CELL KINASE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; KI 67 ANTIGEN; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; BLK GENE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FGR GENE; FYN GENE; GENE; GENE EXPRESSION; HCK GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LCK GENE; LYN GENE; MAJOR CLINICAL STUDY; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TISSUE MICROARRAY; YES GENE; BREAST TUMOR; COHORT ANALYSIS; ENZYMOLOGY; GENETICS; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SRC-FAMILY KINASES;

EID: 77956430031     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605829     Document Type: Article

References (40)

1. Bates RC, Edwards NS, Burns GF, Fisher DE (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 61: 5275-5283
2. Belka C, Marini P, Lepple-Wienhues A, Budach W, Jekle A, Los M, Lang F, Schulze-Osthoff K, Gulbins E, Bamberg M (1999) The tyrosine kinase lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation. Oncogene 18: 4983-4992
3. Bolen JB, Veillette A, Schwartz AM, DeSeau V, Rosen N (1987) Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 84: 2251-2255 (Pubitemid 17075849)
4. Brown MT, Cooper JA (1996) Regulation, substrates and functions of src. Biochim Biophys Acta 1287: 121-149
5. Campbell EJ, McDuff E, Tatarov O, Tovey S, Brunton V, Cooke TG, Edwards J (2008) Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br J Cancer 99: 1769-1774
6. Canna K, Hilmy M, McMillan DC, Smith GW, McKee RF, McArdle CS, McNicol AM (2008) The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis 10: 663-667
7. Chakraborty G, Rangaswami H, Jain S, Kundu GC (2006) Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. J Biol Chem 281: 11322-11331
8. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR (2010) LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 70: 2296-2306
9. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, Cooke TG, Brunton VG, Edwards J (2009) Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR-and HER2-negative breast cancer patients? Am J Pathol 175: 1389-1397
10. Engen JR, Wales TE, Hochrein JM, Meyn III MA, Banu OS, Bahar I, Smithgall TE (2008) Structure and dynamic regulation of Src-family kinases. Cell Mol Life Sci 65: 3058-3073
11. Frame MC (2002) Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602: 114-130
12. Fu Y, Zagozdzon R, Avraham R, Avraham HK (2006) CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion. Int J Oncol 29: 1453-1458
13. Gee JM, Shaw VE, Hiscox SE, McClelland RA, Rushmere NK, Nicholson RI (2006) Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocr Relat Cancer 13(Suppl 1): S77-S88
14. Goldenberg-Furmanov M, Stein I, Pikarsky E, Rubin H, Kasem S, Wygoda M, Weinstein I, Reuveni H, Ben Sasson SA (2004) Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 64: 1058-1066
15. Hibbs ML, Dunn AR (1997) Lyn, a src-like tyrosine kinase. Int J Biochem Cell Biol 29: 397-400
16. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97: 263-274
17. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F, Shaw P, Clark E (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67: 2226-2238 (Pubitemid 46424242)
18. Hynes NE (2000) Tyrosine kinase signalling in breast cancer. Breast Cancer Res 2: 154-157
19. Irby RB, Yeatman TJ (2000) Role of Src expression and activation in human cancer. Oncogene 19: 5636-5642
20. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett JM (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48: 787-794
21. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Grone HJ, Ganten TM, Sultmann H, Tuttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13: 235-248
22. Lee F, Fandi A, Voi M (2008) Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 40: 334-343
23. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA (2006) Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregula-tors associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20: 3120-3132
24. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298: 1912-1934
25. Martin GS (2001) The hunting of the Src. Nat Rev Mol Cell Biol 2: 467-475
26. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, Li JQ, Yoneyama H, Uchida N, Fujita J, Yoshiji H, Watanabe S, Kurokohchi K, Kuriyama S (2003) pp60c-src activation in lung adenocarcinoma. Eur J Cancer 39: 1447-1455
27. Palacios EH, Weiss A (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23: 7990-8000
28. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE (2008) Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68: 3323-3333
29. Reed JC (1999) Dysregulation of apoptosis in cancer. J Clin Oncol 17: 2941-2953
30. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M (2009) T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 11: R15
31. Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ (1999) Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 13: 855-861
32. Rudner J, Mueller AC, Matzner N, Huber SM, Handrick R, Belka C, Jendrossek V (2009) The additional loss of Bak and not the lack of the protein tyrosine kinase p56/Lck in one JCaM1.6 subclone caused pronounced apoptosis resistance in response to stimuli of the intrinsic pathway. Apoptosis 14: 711-720
33. Samraj AK, Stroh C, Fischer U, Schulze-Osthoff K (2006) The tyrosine kinase Lck is a positive regulator of the mitochondrial apoptosis pathway by controlling Bak expression. Oncogene 25: 186-197
34. Stehelin D, Guntaka RV, Varmus HE, Bishop JM (1976) Purification of DNA complementary to nucleotide sequences required for neoplastic transformation of fibroblasts by avian sarcoma viruses. J Mol Biol 101: 349-365
35. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J (2009) SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res 15: 3540-3549
36. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM (2005) Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 11: 4835-4842
37. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A, Rijksen G (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180: 383-388
38. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW, Buchdunger E, Forster K, Moarefi I, Hallek M (2003) Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 101: 664-672
39. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE (2002) Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 21: 8075-8088
40. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4: 470-480